Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
适用于评估免疫检查点抑制剂的高渗透性和免疫原性非病毒性肝癌小鼠模型
基本信息
- 批准号:10056211
- 负责人:
- 金额:$ 55.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-12-01 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAffectAlcoholic steatohepatitisAlcoholsAntigensCarbohydratesCarcinogen exposureCell LineCell SurvivalCholesterolChronicCodeDataData SetDatabasesDevelopmentDietDiethylnitrosamineDisadvantagedDistantEnergy IntakeEtiologyEuropeEvaluationEventFatty acid glycerol estersFructoseFutureGenomicsGoalsGrowthHepatitis B VirusHepatitis C virusHigh Fat DietHumanImmuneImmune checkpoint inhibitorIncidenceInfectionInsulin ResistanceLaboratoriesLinkLiquid substanceLiver neoplasmsMHC Class I GenesMalignant NeoplasmsModelingMusMutationNatureNon-Insulin-Dependent Diabetes MellitusPD-1 inhibitorsPD-1/PD-L1PD-L1 blockadePathogenicityPatternPenetrancePharmaceutical PreparationsPoint MutationPrimary carcinoma of the liver cellsProtocols documentationResearch Project GrantsSeriesTestingTherapeuticTherapeutic UsesTimeTissuesTranslational ResearchTransplantationTumor Antigensalcohol exposurecarcinogenicitycell growthcheckpoint inhibitioncomputerized toolsdriver mutationdrug testingefficacy testingendoplasmic reticulum stressexomeexperimental studyfeedinggenomic datagenomic profileshepatocellular carcinoma cell linehuman modelimmune checkpoint blockadeimmunogenicimprovedin vivo imagingin vivo monitoringinnovationmortalitymouse modelneoplastic cellnon-alcoholicnonalcoholic steatohepatitisnovelnovel drug classobjective response ratepreventprogrammed cell death ligand 1real time monitoringresponsesaturated fatsuccesssugartooltranscriptomicstranslational modeltransplant modeltreatment responsetumortumor growthtumorigenicwhole genome
项目摘要
PROJECT SUMMARY
This application, “Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for
evaluation of immune checkpoint inhibitors”, is submitted in response to FOA PAR-17-245 “Research Projects
to Enhance Applicability of Mammalian Models for Translational Research”. The goal of this project is to develop
accurate, innovative, and immunogenic mouse models of hepatocellular carcinoma (HCC) that closely mimic the
main etiologies of human non-viral HCC in their pathogenic, transcriptomic, and genomic profiles. These
etiologies include non-alcoholic (NASH) and alcoholic (ASH) steatohepatitis, and type 2 diabetes (T2D).
Although the current major etiologies that underlie HCC development are hepatitis virus B and C (HBV, HCV)
infections, non-viral HCC is predicted to become the major form of this aggressive cancer in the US and Europe
in the not too distant future. While the incidence of non-viral HCC and its associated mortality continue to grow
at an alarming rate, progress in HCC treatment has been disappointingly slow. Recently, however, inhibitors of
the PD-1:PD-L1 checkpoint were found to be much more effective in HCC treatment than any other targeted or
non-targeted therapeutic used in the past. Nonetheless, with objective response rates around 20%, there is much
room for future improvement. Such improvement depends on better understanding of how immune checkpoint
inhibition leads to HCC regression and the identification of adjuvants that enhance the response to this new class
of drugs. Both objectives are dependent on the availability of immunogenic mouse models of human HCC. We
will bank on our recent success in developing an immunogenic mouse model of NASH-driven HCC that is
responsive to PD-1/PD-L1 blockade to develop new and improved mouse models of non-viral HCC that show
rapid and synchronized tumor development, making them highly useful for translational research. In addition to
NASH-driven HCC, we will develop new immunogenic models of ASH-driven HCC. We will also generate a
series of mouse HCC-derived cell lines that give rise to synchronized orthotopic tumors, whose growth and
response to treatment can be monitored by in vivo imaging. To determine and demonstrate the human relevance
of these models, they will be subjected to extensive genomic and transcriptomic characterization and
immunoprofiling. The results of these analyses will be compared to the genomic and transcriptomic profiles of
human HCC using innovative computational tools. The following Specific Aims will be pursued: 1) Use the MUP-
uPA model of NASH driven HCC to compare the carcinogenic efficacy of different NASH-related diets; 2) Use
the MUP-uPA mouse to develop new models of ASH-induced HCC that do not involve HFD feeding; 3) Compare
mouse and human HCC genomic, transcriptomic, and immune profiles; and 4) Generate cell lines from the
different mouse HCC models that will give rise to synchronized orthotopic tumors that are useful for drug testing.
项目摘要
该申请,“适用于非病毒性肝癌的高渗透性和免疫原性小鼠模型
免疫检查点抑制剂的评价”,是响应FOA PAR-17-245“研究项目”提交的
提高哺乳动物模型在转化研究中的适用性”。该项目的目标是开发
准确、创新和免疫原性的肝细胞癌(HCC)小鼠模型,
人类非病毒性HCC的致病性、转录组学和基因组学特征的主要病因。这些
病因包括非酒精性(NASH)和酒精性(ASH)脂肪性肝炎和2型糖尿病(T2 D)。
虽然目前肝细胞癌发展的主要病因是肝炎病毒B和C(HBV,HCV)
在美国和欧洲,非病毒性HCC预计将成为这种侵袭性癌症的主要形式。
在不久的将来。虽然非病毒性HCC的发病率及其相关死亡率持续增长,
以惊人的速度,HCC治疗的进展一直令人不安地缓慢。然而,最近,
发现PD-1:PD-L1检查点在HCC治疗中比任何其它靶向或
过去使用的非靶向治疗。尽管如此,客观答复率在20%左右,
未来改进的空间。这种改善取决于更好地理解免疫检查点如何
抑制导致HCC消退,并鉴定出增强对这种新类型应答的佐剂
毒品这两个目标都依赖于人HCC免疫原性小鼠模型的可用性。我们
我们最近成功开发了一种NASH驱动的HCC免疫原性小鼠模型,
对PD-1/PD-L1阻断有反应,以开发新的和改进的非病毒HCC小鼠模型,
快速和同步的肿瘤发展,使它们对转化研究非常有用。除了
NASH驱动的HCC,我们将开发新的免疫原性模型的ASH驱动的HCC。我们还将生成一个
一系列小鼠肝癌衍生的细胞系,产生同步原位肿瘤,其生长和
对治疗的反应可以通过体内成像来监测。为了确定和证明人类的相关性
在这些模型中,它们将受到广泛的基因组和转录组学表征,
免疫分析这些分析的结果将与以下的基因组和转录组谱进行比较:
人类肝癌的研究。将追求以下具体目标:1)使用内务部警察-
NASH驱动的HCC的uPA模型,以比较不同NASH相关饮食的致癌功效; 2)使用
MUP-uPA小鼠开发不涉及HFD喂养的新的ASH诱导的HCC模型; 3)比较
小鼠和人HCC基因组、转录组和免疫谱;和4)从HCC中产生细胞系。
不同的小鼠HCC模型将产生用于药物测试的同步原位肿瘤。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Karin其他文献
Michael Karin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Karin', 18)}}的其他基金
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
NF-kappaB 和线粒体信号作为炎症的正向和负向调节剂
- 批准号:
10516935 - 财政年份:2023
- 资助金额:
$ 55.25万 - 项目类别:
A new mouse model for studying the pathogenesis and immunobiology of intrahepatic cholangiocarcinoma and improving its immunotherapy
研究肝内胆管癌发病机制和免疫生物学并改进其免疫治疗的新小鼠模型
- 批准号:
10711615 - 财政年份:2023
- 资助金额:
$ 55.25万 - 项目类别:
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
胶原及其裂解产物对 PDAC 代谢和免疫的调节
- 批准号:
10708168 - 财政年份:2022
- 资助金额:
$ 55.25万 - 项目类别:
Regulation of PDAC metabolism and immunity by collagen and its cleavage products
胶原及其裂解产物对 PDAC 代谢和免疫的调节
- 批准号:
10517874 - 财政年份:2022
- 资助金额:
$ 55.25万 - 项目类别:
The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism
NRF2-FBP1 交叉调节环路以及健康和患病肝脏代谢的控制
- 批准号:
10503841 - 财政年份:2022
- 资助金额:
$ 55.25万 - 项目类别:
The NRF2-FBP1 crossregulatory loop and the control of healthy and diseased liver metabolism
NRF2-FBP1 交叉调节环路以及健康和患病肝脏代谢的控制
- 批准号:
10670920 - 财政年份:2022
- 资助金额:
$ 55.25万 - 项目类别:
The effect of cancer cell produced collagen 1 homotrimers on DDR1 signaling activation by microenvironmental collagen 1 fragments.
癌细胞产生的胶原蛋白 1 同源三聚体对微环境胶原蛋白 1 片段激活 DDR1 信号传导的影响。
- 批准号:
10831212 - 财政年份:2022
- 资助金额:
$ 55.25万 - 项目类别:
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
NF-kappaB 和线粒体信号作为炎症的正向和负向调节剂
- 批准号:
10182897 - 财政年份:2020
- 资助金额:
$ 55.25万 - 项目类别:
NF-kappaB and Mitochondrial Signals as Positive and Negative Regulators of Inflammation
NF-kappaB 和线粒体信号作为炎症的正向和负向调节剂
- 批准号:
10266224 - 财政年份:2020
- 资助金额:
$ 55.25万 - 项目类别:
Control of Lipogenesis and Hepatic Steatosis by Caspase-2
Caspase-2 对脂肪生成和肝脂肪变性的控制
- 批准号:
10322660 - 财政年份:2019
- 资助金额:
$ 55.25万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 55.25万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 55.25万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 55.25万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 55.25万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 55.25万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 55.25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 55.25万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 55.25万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 55.25万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 55.25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists